What Trump’s Psychedelics Executive Order Means for Psilocybin
The April 18, 2026 executive order names ibogaine twice. It does not mention psilocybin by name anywhere in the text. And yet, in the forty-eight hours after President Trump signed the order, the psilocybin stock — Compass Pathways — jumped 25 percent in premarket trading, its CEO issued a detailed response welcoming the directive, and FDA Commissioner Marty Makary signaled that three serotonin 2A agonists (the receptor family that includes psilocybin) would receive priority vouchers within the week.
Here is the paradox of this executive order: ibogaine got the political spotlight because of Joe Rogan, Marcus Luttrell, and the veterans’ lobby. But psilocybin is almost certainly the molecule that reaches FDA approval first — and the order just shortened the timeline.
Looking for treatment? Find psilocybin retreats near you as well as other psychedelic therapies in your area.
| Pathway | Before the Executive Order | After the Executive Order |
|---|---|---|
| FDA review for COMP360 (Compass Pathways psilocybin) | Rolling NDA in progress; standard 6–10 month review | Priority voucher likely; review compressible to 1–2 months |
| DEA rescheduling after approval | Undefined, potentially years of delay | Attorney General directed to initiate review upon Phase 3 completion and FDA approval |
| Right to Try for investigational psilocybin | Theoretically available but rarely used | Explicit federal directive to build the pathway |
| State-regulated programs (Oregon, Colorado, New Mexico) | Operating independently of FDA pathway | Federal legitimization; possible ARPA-H funding tailwind |
| Insurance reimbursement for psilocybin therapy | Impossible without federal approval | Becomes conceivable post-approval and post-rescheduling |
| First FDA-approved psilocybin medicine | Expected 2027 best case | Possible late 2026 or early 2027 with priority voucher |
This article walks through what the executive order specifically changes for psilocybin, how it reshapes the race between the pharmaceutical and state-regulated models, and what it means for patients, clinicians, and clinic operators planning for the next two to three years.
Why Psilocybin Is the Real Near-Term Story
The executive order’s most consequential provision for psilocybin is in Section 2(a): the Commissioner of Food and Drugs shall provide Commissioner’s National Priority Vouchers to appropriate psychedelic drugs that have received Breakthrough Therapy designation.
Psilocybin has held Breakthrough Therapy designation from the FDA for years — first for treatment-resistant depression, later for major depressive disorder. Compass Pathways’ synthetic psilocybin product, COMP360, reported its first Phase 3 win in June 2025 for treatment-resistant depression and a second positive Phase 3 readout in February 2026. The company is currently conducting a rolling NDA submission with the FDA, with full submission expected in Q4 2026.
In plain numbers: a standard FDA review for COMP360 would take six to ten months. A Priority Voucher can cut that to roughly one to two months. If Compass receives a voucher and completes its rolling submission on its current timeline, an FDA-approved psilocybin medicine becomes possible in late 2026 or early 2027. That is dramatically faster than what the psychedelic industry was planning for even a month ago.
There is a wrinkle here worth knowing about. STAT News reported in February 2026 that Compass’s COMP360 had been on an initial internal list to receive a CNPV but that the White House removed it. The executive order’s decision to explicitly invoke priority vouchers for psychedelics suggests either a reversal of that decision or an effort to broaden the pool of eligible products. Harvard’s Glenn Cohen has publicly called this one of the more mysterious aspects of the order. Either way, Makary’s subsequent indication that three psychedelics will receive vouchers soon — with Compass and Definium Therapeutics (DT120 for generalized anxiety disorder) the two most obvious candidates — suggests the near-term path has opened.
Right to Try for Psilocybin: Closer Than It Looks for Ibogaine
Section 2(b) of the executive order directs the FDA and DEA to establish a Right to Try pathway for eligible patients to access investigational psychedelic drugs. The order mentions ibogaine specifically, but the language applies to the broader category.
Right to Try requires a completed Phase 1 trial, among other drug-eligibility criteria (full breakdown in our Right to Try explainer). Ibogaine has no completed U.S. Phase 1 trial. Psilocybin has many — COMP360 alone has been through extensive Phase 1, Phase 2, and now Phase 3 studies. The drug-eligibility bar is already cleared for several psilocybin products.
What this means practically: if the DEA issues Schedule I handling authorizations for treating physicians as the executive order directs, Right to Try access for investigational psilocybin could become available faster than for ibogaine. The real bottleneck is not regulatory mechanics but manufacturer willingness. Compass has been clear it is focused on the NDA pathway and full FDA approval, which will serve a vastly larger patient population than Right to Try ever could. Don’t expect Compass to become a large-scale Right to Try provider. Smaller sponsors with earlier-stage psilocybin products may be more open to it.
For patients with severe, treatment-resistant depression and documented failed therapies, Right to Try for psilocybin is going to become a real — if narrow — option within 12 to 18 months.
The State-Regulated Programs: Oregon, Colorado, New Mexico
Psilocybin occupies a unique position in U.S. drug policy because it is both a federally Schedule I substance and a legally accessible therapy in three states. Oregon launched its psilocybin services program in 2023 under the Oregon Psilocybin Services Act, becoming the first state to offer state-regulated adult psilocybin services. Colorado followed in 2025 with a broader “natural medicine” framework. New Mexico is preparing to launch a more narrowly medical model in 2027.
These programs are not pharmaceutical pathways. They do not require a prescription, they do not involve the FDA, and they have never depended on federal rescheduling. Adults access psilocybin through licensed service centers or healing centers, under the supervision of trained facilitators, for sessions that typically cost around $2,500.
The executive order does not directly change any of this. But it reshapes the competitive and political landscape in three important ways.
Federal legitimization. For three years, state-regulated psilocybin programs have operated under a cloud of federal skepticism. A sitting president endorsing psychedelic medicine — even if the endorsement is specifically about FDA-approvable products — makes it harder for federal agencies to interfere with state programs. Oregon and Colorado facilitators woke up on April 19 in a friendlier regulatory environment than they went to sleep in on April 17.
ARPA-H funding accessibility. Section 3 allocates at least $50 million through ARPA-H for federal-state collaboration on psychedelic research. Oregon and Colorado, with the most developed state infrastructure and growing real-world evidence bases, are obvious candidates for federal research partnership funding. A February 2026 medRxiv paper analyzing Oregon’s program found clinically meaningful improvements in depression, anxiety, and well-being 30 days post-session — the kind of real-world evidence the ARPA-H directive explicitly contemplates.
The existential question about the FDA-approved product. Once Compass’s COMP360 is FDA-approved and psilocybin (in that specific pharmaceutical formulation) is rescheduled, the state-regulated model faces a harder question. Oregon and Colorado will likely continue to operate — the programs are state law and the FDA has no jurisdiction over state-licensed facilitators administering natural psilocybin products. But insurance coverage will flow to the pharmaceutical version. Some patients who would have paid $2,500 out of pocket for an Oregon session may instead seek a Spravato-style clinic offering the FDA-approved synthetic psilocybin under insurance. The state programs’ struggle is already visible: a third of Oregon’s service centers have closed according to January 2026 reporting by the New York Times, citing high costs and low awareness. The FDA approval of a covered alternative could accelerate this pressure, even as the broader federal endorsement of psilocybin validates the underlying science.
What It Means for Ketamine Clinics and Psychedelic Practitioners
If you operate a ketamine clinic or a Spravato-certified practice, the psilocybin angle of the executive order matters even though psilocybin is not yet available as a prescription drug. Three practical implications.
Your infrastructure will likely fit. An FDA-approved psilocybin therapy — if Compass’s COMP360 clears — will almost certainly come with a REMS that requires certified prescribers, certified clinics, in-clinic dosing with observation, and adverse-event reporting. The structural requirements will closely resemble what Spravato already demands. Clinics that have built that operational muscle will be first in line to add psilocybin when it arrives.
Patient expectations are shifting fast. Compass has publicly stated COMP360’s effects can be durable for at least six months after just one or two doses. That is a different therapeutic economics than six times a year ketamine maintenance. Clinics should be thinking now about how a longer-duration, deeper-intervention therapy fits alongside or replaces existing ketamine protocols.
The session format is different. Psilocybin sessions from the Compass protocol run approximately six hours. MM120 (Definium’s LSD-based candidate, also likely to benefit from the executive order) runs approximately eight hours. Compare that to Spravato’s roughly two-hour visit. Clinics planning to add these therapies will need to fundamentally rethink space, staffing, and scheduling. The clinics that plan for this now will be ready when the approvals arrive.
Timeline: What to Watch
Next 30 days. The FDA issues its first Priority Vouchers. Compass and Definium are the widely expected recipients, but Makary has not yet named specific companies. Watch for the announcement in the next week.
Next 6 months. DEA guidance on Schedule I handling authorizations for Right to Try. Compass continues rolling submission toward full NDA. Oregon and Colorado programs seek ARPA-H collaboration funding.
Next 12 months. Compass’s NDA is fully submitted, likely by Q4 2026. If priority review is granted, an FDA action could come in late 2026 or early 2027. Right to Try requests for investigational psilocybin begin to test the pathway.
Next 18–36 months. First FDA-approved psilocybin medicine launches, likely for treatment-resistant depression. DEA rescheduling of that specific product follows per Section 5 of the executive order. REMS framework takes shape. Insurance coding and reimbursement pathways develop. State-regulated programs adapt to the new competitive landscape.
The Bottom Line
The ibogaine headlines from the executive order are loud and politically resonant. The psilocybin story is quieter, more technical, and arguably more consequential. For the first time, the conditions for an FDA-approved psilocybin medicine arriving in American pharmacies are real and near. A drug that was decriminalized in Denver in 2019 could be a prescription in Denver by 2027.
For patients with treatment-resistant depression, that is not an abstraction. It is a timeline. And the April 18 executive order just moved it forward.
RELATED: What Trump’s Psychedelics Executive Order Actually Means for Ibogaine | Right to Try Ibogaine: What the New Federal Pathway Actually Offers | Comparing Psilocybin Access Programs in Oregon, Colorado, and New Mexico | 2026 Could Be the Year Psychedelics Finally Break Through
